Results 131 to 140 of about 22,516 (228)

Metastatic Prostate Cancer: Impact of Site on Oncological Outcomes in Japanese Patients. [PDF]

Res Rep Urol
Arinami K, Tsuboya K, Ito K, Kondo S, Takizawa Y, Ikeda Y, Kawaguchi G, Hara N, Nishiyama T.   +8 more
europepmc   +1 more source

Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer. [PDF]

Oncogene
Gao Y, Liu Y, Ye X, Liu A, Li X, Hu S, Chen X, Ma Q, Mo L, Jiang L, Tan L, Du Y, Zheng Y, Yang J, Luo G, Zhao Z, Shi X.   +16 more
europepmc   +1 more source

Real-World Outcomes of Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation. [PDF]

Int J Urol
Abe K, Miyazawa Y, Nakazawa S, Onose M, Maeno Y, Tsuji Y, Kanayama A, Ohtsu A, Fujizuka Y, Arai S, Nomura M, Sekine Y, Koike H, Matsui H, Suzuki K.   +14 more
europepmc   +1 more source

Gut-prostate axis in prostate cancer: microbiome signatures, mechanistic insights, and therapeutic opportunities. [PDF]

Front Cell Infect Microbiol
Wang K, Tang Q, Fan W, Su Q.
europepmc   +1 more source

NGS-Based Genomic Profiling Identifies Independent Predictors of Time to Castration Resistance in Hormone-Sensitive Prostate Cancer: A Retrospective Real-World Study. [PDF]

Curr Oncol
Turan M, Balta MÇ.
europepmc   +1 more source

[Comparison of clinical outcomes between radical prostatectomy and permanent prostate brachytherapy in patients with oligometastatic prostate cancer: A propensity score-matched study]. [PDF]

Beijing Da Xue Xue Bao Yi Xue Ban
Su D, Li B, Xiao R, Zhang F, Zhang S.
europepmc   +1 more source

Docosahexaenoic Acid Enhances the Cytotoxic Effects of Enzalutamide and the PARP Inhibitor in Castration-Resistant Prostate Cancer Cell Lines. [PDF]

Int J Mol Sci
da Silva ADT, Ferreira LDP, Ribeiro DL, Tamarindo GH, Góes RM.   +4 more
europepmc   +1 more source

Correction: Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. [PDF]

Sci Rep
Wang Z, Xiao H, Zheng C, Chen J, Chen Q, Chen Z, Zhang D, Wang L, Lan W, Liu Q, Jiang J.   +10 more
europepmc   +1 more source

Abiraterone in elderly patients with CRPC [PDF]

Nature Reviews Urology, 2015
openaire   +1 more source

Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review). [PDF]

Int J Mol Med
Yan L, Sun X, Su P.
europepmc   +1 more source